These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 21284356)

  • 1. Fentanyl intranasal. Breakthrough cancer pain: unsafe packaging.
    Prescrire Int; 2010 Nov; 19(110):251. PubMed ID: 21284356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
    Kress HG; OroĊ„ska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
    Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fentanyl nasal spray (Lazanda) for pain.
    Med Lett Drugs Ther; 2011 Dec; 53(1379-1380):99-100. PubMed ID: 22173454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fentanyl buccal tablet (Fentora) for breakthrough pain.
    Med Lett Drugs Ther; 2007 Sep; 49(1270):78-9. PubMed ID: 17878889
    [No Abstract]   [Full Text] [Related]  

  • 5. Fentanyl effervescent buccal tablets: new formulation. For cancer patients with breakthrough pain: a second buccal formulation with minimal evaluation.
    Prescrire Int; 2009 Oct; 18(103):205. PubMed ID: 19882786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM; Messina J; Xie F; Hale M
    Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain.
    Davies A; Sitte T; Elsner F; Reale C; Espinosa J; Brooks D; Fallon M
    J Pain Symptom Manage; 2011 Feb; 41(2):358-66. PubMed ID: 21334555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: appropriate patient selection and management.
    Fine PG; Narayana A; Passik SD
    Pain Med; 2010 Jul; 11(7):1024-36. PubMed ID: 20642730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breakthrough pain: progress in management.
    Lossignol DA; Dumitrescu C
    Curr Opin Oncol; 2010 Jul; 22(4):302-6. PubMed ID: 20489619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal fentanyl in cancer patients with moderate-to-severe pain: a prospective examination.
    Iconomou G; Viha A; Vagenakis AG; Kalofonos HP
    Anticancer Res; 2000; 20(6C):4821-4. PubMed ID: 11205226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral transmucosal fentanyl: new preparation. For breakthrough cancer pain when morphine fails.
    Prescrire Int; 2002 Aug; 11(60):106-7. PubMed ID: 12199262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety alert for fentanyl buccal tablets.
    U.S. Food and Drug Administration
    J Pain Palliat Care Pharmacother; 2008; 22(1):47. PubMed ID: 19062355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: A prospective, randomized, double-blind, placebo-controlled study.
    Veldhorst-Janssen NM; Fiddelers AA; van der Kuy PH; Kessels AG; Theunissen HM; van der Hulst RR; Neef C; Marcus MA
    Clin Ther; 2010 Jul; 32(7):1427-36. PubMed ID: 20678689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
    Dietrich E; Gums JG
    Ann Pharmacother; 2012 Oct; 46(10):1382-91. PubMed ID: 23012382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Breakthrough pain frequency in cancer patients and the efficiency of oral transmucosal fentanyl citrate].
    Bilen A; Ali A; Baturay F; Altan A
    Agri; 2010 Jul; 22(3):103-8. PubMed ID: 20865581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral transmucosal fentanyl citrate--OTFC (ACTIQ) #103.
    Gordon D; Schroeder M
    J Palliat Med; 2008 May; 11(4):633-4. PubMed ID: 18454617
    [No Abstract]   [Full Text] [Related]  

  • 17. Intranasal fentanyl in 1-3-year-olds: a prospective study of the effectiveness of intranasal fentanyl as acute analgesia.
    Cole J; Shepherd M; Young P
    Emerg Med Australas; 2009 Oct; 21(5):395-400. PubMed ID: 19840089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-controlled intranasal analgesia: effective alternative to intravenous PCA for postoperative pain relief.
    Toussaint S; Maidl J; Schwagmeier R; Striebel HW
    Can J Anaesth; 2000 Apr; 47(4):299-302. PubMed ID: 10764171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain.
    Mercadante S; Villari P; Ferrera P; Casuccio A; Mangione S; Intravaia G
    Br J Cancer; 2007 Jun; 96(12):1828-33. PubMed ID: 17519902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain.
    Zeppetella G
    Palliat Med; 2000 Jan; 14(1):57-8. PubMed ID: 10717724
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.